Literature DB >> 16114292

[Increasing trend in prescription of methylphenidate in general practices in the north-east of The Netherlands, 1998-2003].

G A Donker1, F Groenhof, W J van der Veen.   

Abstract

OBJECTIVE: To obtain information on the frequency of and the indications for prescription of methylphenidate in general practices in the north-east of The Netherlands.
DESIGN: Descriptive.
METHOD: Data were collected from 1998 to 2003 from 6 general practices in the north-east of The Netherlands (17 general practitioners, approximately 30,000 patients) that were affiliated to the Registration Network in Groningen. The number of new and existing patients who were prescribed methylphenidate was calculated by age group per 1000 person-years per calendar year. The indication on which the drug was prescribed was looked at, as was the number of patients who were referred to a specialist on that indication.
RESULTS: The number of new users per 1000 person-years more than doubled from 17 in 1999 to 42 in 2003. In all years studied the highest number of new users fell into the age group 5-9 years. The total number of users per 1000 person-years tripled (boys: 1.8 in 1998 and 6.2 in 2003; girls: 0.5 in 1998 and 0.8 in 2003). The prevalence of use in boys was 3 to 8 times as high as that of girls and increasing more quickly. In people under 59 years of age attention deficit hyperactivity disorder (ADHD) was the most frequent indication (55%). In the group aged > or = 60 years methylphenidate was mainly prescribed in the palliative phase of somatic morbidity. Over half of the 140 new patients (57%) were referred nor to a specialist in the year before neither in the year after the first prescription of methylphenidate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16114292

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  5 in total

1.  Use of attention-deficit/hyperactivity disorder medication among older adults in Denmark.

Authors:  Stina Schultz Ormhøj; Anton Pottegård; Christiane Gasse; Lotte Rasmussen
Journal:  Br J Clin Pharmacol       Date:  2018-04-22       Impact factor: 4.335

2.  Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.

Authors:  Els van den Ban; Patrick C Souverein; Hanna Swaab; Herman van Engeland; Toine C G Egberts; Eibert R Heerdink
Journal:  Atten Defic Hyperact Disord       Date:  2010-11-30

Review 3.  Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.

Authors:  Christopher Steer; Jan Froelich; César A Soutullo; Mats Johnson; Monica Shaw
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 6.497

4.  Methylphenidate and the response to growth hormone treatment in short children born small for gestational age.

Authors:  Judith S Renes; Maria A J de Ridder; Petra E Breukhoven; Annemieke J Lem; Anita C S Hokken-Koelega
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

5.  Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence.

Authors:  Michael Schlander
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2007-11-15       Impact factor: 3.033

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.